Otsuka will co-promote with Boryung to maintain IMD Mucosta SR in the Rebamipide market. The gastrointestinal drug Rebamipide market, worth ₩100 billion, has recently been fiercely competitive. In December of last year, Yuhan (Recomid SR), GC Pharma (Mucotect SR), Daewoong Pharmaceutical (Mucotra SR), and Daewon Pharmaceutical (Bidreba SR) were approved for IMD of Rebamipide.

While Rebamipide is taken three times a day, these IMDs are taken twice a day. A competitive drug has been released in the existing market where generics have been the only so far.

The launch of IMDs affected Mucosta's sales, which account for about 10% of Otsuka's total sales. Mucosta recorded ₩17.3 b